Brokerages Set Ocular Therapeutix Inc (OCUL) PT at $13.67

Shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have earned an average rating of “Buy” from the eight research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $13.67.

A number of brokerages recently issued reports on OCUL. Cantor Fitzgerald set a $22.00 price objective on shares of Ocular Therapeutix and gave the company a “buy” rating in a report on Tuesday, August 7th. Zacks Investment Research raised shares of Ocular Therapeutix from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a report on Wednesday, July 11th. ValuEngine raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Thursday, August 9th. JMP Securities set a $9.00 price objective on shares of Ocular Therapeutix and gave the company a “buy” rating in a report on Monday, August 20th. Finally, BidaskClub raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Thursday, September 27th.

In related news, CFO Donald Notman bought 12,500 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were bought at an average price of $6.29 per share, with a total value of $78,625.00. Following the completion of the transaction, the chief financial officer now directly owns 17,300 shares of the company’s stock, valued at approximately $108,817. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Antony C. Mattessich bought 16,900 shares of the firm’s stock in a transaction on Friday, August 10th. The stock was bought at an average cost of $6.23 per share, for a total transaction of $105,287.00. Following the transaction, the insider now directly owns 37,900 shares of the company’s stock, valued at $236,117. The disclosure for this purchase can be found here. Insiders acquired 49,400 shares of company stock worth $302,912 in the last ninety days. 15.90% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Jennison Associates LLC lifted its position in Ocular Therapeutix by 1.2% in the second quarter. Jennison Associates LLC now owns 2,319,255 shares of the biopharmaceutical company’s stock valued at $15,655,000 after buying an additional 26,503 shares during the last quarter. BlackRock Inc. lifted its position in Ocular Therapeutix by 15.9% in the second quarter. BlackRock Inc. now owns 1,965,882 shares of the biopharmaceutical company’s stock valued at $13,270,000 after buying an additional 269,270 shares during the last quarter. Opaleye Management Inc. acquired a new position in Ocular Therapeutix in the second quarter valued at about $7,499,000. Deltec Asset Management LLC lifted its position in Ocular Therapeutix by 16.3% in the third quarter. Deltec Asset Management LLC now owns 619,945 shares of the biopharmaceutical company’s stock valued at $4,266,000 after buying an additional 86,959 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Ocular Therapeutix by 11.7% in the second quarter. Northern Trust Corp now owns 362,627 shares of the biopharmaceutical company’s stock valued at $2,447,000 after buying an additional 38,101 shares during the last quarter. 56.96% of the stock is currently owned by institutional investors.

Shares of OCUL traded up $0.09 during mid-day trading on Thursday, reaching $5.24. The stock had a trading volume of 206,667 shares, compared to its average volume of 371,910. The company has a debt-to-equity ratio of 0.21, a current ratio of 4.92 and a quick ratio of 4.91. Ocular Therapeutix has a 52-week low of $3.30 and a 52-week high of $8.28.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.37). Ocular Therapeutix had a negative net margin of 2,814.72% and a negative return on equity of 143.32%. The firm had revenue of $0.65 million during the quarter, compared to analyst estimates of $0.35 million. On average, sell-side analysts anticipate that Ocular Therapeutix will post -1.53 earnings per share for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

See Also: Book Value Of Equity Per Share – BVPS Explained

Analyst Recommendations for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply